Maintenance azithromycin therapy reduces asthma exacerbations

  • Hiles SA & al.
  • Eur Respir J
  • 1 Nov 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This meta-analysis suggests that long-term use of azithromycin with existing maintenance asthma treatment reduces the risk for exacerbations in patients with asthma and in severe asthma, eosinophilic asthma and non-eosinophilic asthma sub-phenotypes.

Why this matters

  • The 2019 Global Initiative for Asthma guidelines recommend the use of macrolides as an add-on therapy in patients with difficult-to-treat and severe asthma, despite no published data.
  • Azithromycin may be a useful adjunct medication for well-selected at risk, as it is inexpensive, easily administered and effective at reducing exacerbations.

Study design

  • Meta-analysis of 3 studies (n=597) that compared at least 8 weeks of azithromycin treatment with placebo.
  • Exacerbations in asthma assessed over at least 6 months
  • Funding: None.

Key results

  • During follow-up, azithromycin treatment was associated with a reduction in the rate of asthma exacerbation (incidence rate ratio [IRR], 0.61; 95% CI, 0.49-0.78; P<.001>
  • Reduced rate was similar in:
    • non-eosinophilic (IRR, 0.61; 95% CI, 0.45-0.82; P=.001);
    • eosinophilic (IRR, 0.63; 95% CI, 0.44-0.92; P=.015); and
    • severe (IRR, 0.69; 95% CI, 0.52-0.92; P=.013) asthma.
  • In patients with eosinophilic asthma, azithromycin group had significantly reduced rates of oral corticosteroid course [OCS] courses (IRR, 0.42; 95% CI, 0.23-0.78; P=.006) and reduced likelihood of reporting an OCS course (OR, 0.48; 95% CI, 0.26-0.89; P=.019).
  • Azithromycin therapy was associated with reduction in the rate of antibiotic use for respiratory infections in the entire cohort (IRR=0.54, 95%CI 0.38-0.76, P=.001), non-eosinophilic asthma (IRR=0.36; 95% CI, 0.22-0.56, P<.001 and severe asthma p=".037)</li">
  • Hospitalisation was infrequent, with similar prevalence reported in both the azithromycin and placebo group (OR=0.71, 95% CI 0.32-1.56, P=.390, N=597)

Limitations

  • Limited number of studies.